Chronic hepatitis B virus (HBV) infection is a major risk factor for hepatocellular carcinoma (HCC) and current treatments for chronic hepatitis B and HCC are suboptimal. Herein, we identified cellular serine/threonine Polo-like-kinase 1 (PLK1) as a positive effector of HBV replication. The aim of this study was to demonstrate the proviral role of PLK1 in HBV biosynthesis and validate PLK1 inhibition a potential antiviral strategy. To this end, we employed physiologically relevant HBV infection models of primary human hepatocytes (PHHs) and differentiated HepaRG cells in conjunction with pharmacologic PLK1 inhibitors, small interfering RNA (siRNA)-mediated knockdown, and overexpression of constitutively active PLK1 (PLK1 CA ). In addition, a humanized liver Fah 2/2
1,2
Nathalie Isorce, 1, 2 Franc¸ois-Lo€ ıc Cosset, 2, 4 Fabien Zoulim, 1, 2, 5, 6 Ourania Andrisani, 3 and David Durantel 1, 2, 6 Chronic hepatitis B virus (HBV) infection is a major risk factor for hepatocellular carcinoma (HCC) and current treatments for chronic hepatitis B and HCC are suboptimal. Herein, we identified cellular serine/threonine Polo-like-kinase 1 (PLK1) as a positive effector of HBV replication. The aim of this study was to demonstrate the proviral role of PLK1 in HBV biosynthesis and validate PLK1 inhibition a potential antiviral strategy. To this end, we employed physiologically relevant HBV infection models of primary human hepatocytes (PHHs) and differentiated HepaRG cells in conjunction with pharmacologic PLK1 inhibitors, small interfering RNA (siRNA)-mediated knockdown, and overexpression of constitutively active PLK1 (PLK1   CA   ) . In addition, a humanized liver Fah 2/2
/Rag2
2/2 /Il2rg 2/2 (FRG) mouse model was used to determine the antiviral effect of PLK1 inhibitor BI-2536 on HBV infection in vivo. Finally, in vitro PLK1 kinase assays and site-directed mutagenesis were employed to demonstrate that HBV core protein (HBc) is a PLK1 substrate. We demonstrated that HBV infection activated cellular PLK1 in PHHs and differentiated HepaRG cells. PLK1 inhibition by BI-2536 or siRNA-mediated knockdown suppressed HBV DNA biosynthesis, whereas overexpression of PLK1 CA increased it, suggesting that the PLK1 effects on viral biosynthesis are specific and that PLK1 is a proviral cellular factor. Significantly, BI-2536 administration to HBV-infected humanized liver FRG mice strongly inhibited HBV infection, validating PLK1 as an antiviral target in vivo. The proviral action of PLK1 is associated with the biogenesis of the nucleocapsid, as BI-2536 leads to its decreased intracellular formation/ accumulation. In this respect, our studies identified HBc as a PLK1 substrate in vitro, and mapped PLK1 phosphorylation sites on this protein. Conclusion: PLK1 is a proviral host factor that could be envisaged as a target for combined antiviral and antitumoral strategies against HBV infection and HBV-mediated carcinogenesis. (HEPATOLOGY 2017; 66:1750 -1765 ).
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C hronic hepatitis B virus (HBV) infection is an independent risk factor for development of hepatocellular carcinoma (HCC). (1, 2) Liver cancer is the fifth and seventh most common cancer worldwide according to sex and the third most common in terms of death. With approximately 250 million people chronically infected with HBV, according to the latest World Health Organization estimation, many patients with chronic hepatitis B are expected to progress to HCC, despite existing therapies. (1) Although a prophylactic vaccine is available, new infections still happen because vaccination campaigns are not always well-implemented, and the vaccine is not always 100% protective. (2) Furthermore, children of infected mothers still become chronically infected in endemic areas. (2) Current treatments include use of pegylated interferon-a (IFN-a) and/or antiviral nucleoside analogs; the latter require life-long administration, which can result in viral resistance when drugs with a low genetic barrier are used. (3) New and effective therapies are urgently needed. (3) In particular, drugs that target both viral replication and prevent neoplastic transformation could represent a valuable addition to the therapeutic arsenal.
Replication of HBV within hepatocytes involves both nuclear and cytoplasmic events. (4) After viral entry, nucleocapsids are transported to the nucleus, releasing the viral DNA and core/capsid HBV core protein (HBc) into the nucleoplasm. There, the viral genome, initially a relaxed circular partially doublestranded DNA (rcDNA), is converted into covalently closed circular double-stranded DNA (cccDNA), which is responsible for viral persistence. This nuclear form of the genome serves as a template for viral RNA transcription, including pregenomic RNA (pgRNA). (4) In the cytoplasm, pgRNA interacts with HBV polymerase and is packaged into capsids, where it is reverse-transcribed to generate newly synthesized rcDNA. (4) HBc plays an essential and dynamic role in HBV biosynthesis, including selective binding to pgRNA in association with viral polymerase, encapsidation, and reverse-transcription of pgRNA, transport of mature capsids to the site of viral envelopment for virion generation, and transport to the nucleus for recycling. (5) Although the mechanism by which HBc and capsid assembly regulate viral DNA synthesis is not fully understood, it is well established that phosphorylation of HBc has an important role in various aspects of pgRNA reverse-transcription. (5, 6) Kinases that mediate HBc phosphorylations include cyclindependent kinase 2 (CDK2), which phosphorylates serine/proline (SP) sites located at the C-terminus of HBc, including S155, S162, and S170. (7, 8) Another study has identified additional serine/threonine (S/T) sites as having a role in regulating all aspects of HBV replication, and serine/arginine protein kinase 1 as another kinase that phosphorylates HBc in vitro. (9) Our earlier studies, aiming at understanding the mechanism by which the HBV X protein (HBx) mediates oncogenic transformation of hepatocytes, (10) (11) (12) led us to the study of Polo-like-kinase 1 (PLK1), an S/T kinase involved in cell cycle regulation. (13, 14) In physiologic conditions, PLK1 is required for checkpoint recovery, mitotic entry, and progression, whereas it is overexpressed in many human cancers, including HBV-mediated liver cancer. (13, 14) We have shown that HBx activates PLK1 prematurely, allowing propagation of DNA damage to daughter cells by attenuating both DNA repair and p53 apoptosis. (11, 12) In a cellular model of HBx-mediated transformation and in liver tumors of animals modeling HBx-and HBVmediated hepato-carcinogenesis, expression of PLK1 is elevated. (11, 12, 15, 16) However, whether PLK1 is activated during physiologic HBV infection of normal hepatocytes, and whether it has a role in the establishment and maintenance of infection is unknown. To address this issue, in this study, we used HBV infection models of nontransformed primary human
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hepatocytes (PHHs) and differentiated HepaRG (dHepaRG) cells, a bipotential human dedifferentiated hepatocyte cell line that upon differentiation supports HBV infection. (17, 18) In this study, we demonstrate that the cellular PLK1 enzyme acts as a proviral host factor for HBV replication in vitro by favoring nucleocapsid formation and subsequent reverse transcription. In addition, we identified the viral core protein HBc as a PLK1 substrate in vitro and mapped the sites of PLK1 phosphorylation. Finally, we provide evidence that PLK1 inhibitors serve as a novel class of anti-HBV molecules in vitro and validate the antiviral effect of PLK1 inhibitor BI-2536 in HBV-infected liver humanized mice in vivo.
Materials and Methods

CHEMICALS, ANTIBODIES, AND OTHERS REAGENTS
All chemicals were purchased from Sigma-Aldrich unless specified otherwise. PLK1 inhibitors (BI-2536, BI 6727, MLN 0905, and ON 01910) were from Selleckchem. Polyclonal HBc (19) and commercially available HBc antibodies were used for immunofluorescent staining and immunoblots. Rabbit polyclonal antiHBc was from Dako (B0586) or Abcam (ab140243) and monoclonal anti-HBc from Abcam (ab8637; Clone C1). PLK1 antibodies used: rabbit polyclonal (ab21738) for detection of phospho-PLK1-S 137 in western blotting and immunofluorescence; rabbit monoclonal (ab115095) for detection of phospho-PLK1-T 210 in western blotting and immunofluorescence, and rabbit polyclonal (ab109777) for detection of PLK1. Small interfering RNA (siRNA; SmartPool or sequence designed) were purchased from Dharmacon and transfected into dHepaRG cells or PHHs using Darmafect-1 reagent according to the manufacturer's instructions. Tenofovir (TFV) and HBV capsid assembly inhibitors Bay41-4109 (20) and AT130 (21) were kindly provided by Gilead Sciences and Novira Pharmaceutics, respectively. IFN-a (i.e., Roferon) was obtained from Hoffmann-La-Roche.
HepaRG CELLS AND PRIMARY HUMAN HEPATOCYTES AND INFECTION BY HBV
Human liver progenitor HepaRG cells (18) were cultured for 2 weeks in complete William's medium (Gibco) supplemented with 10% Fetal Clone II serum (Thermo Scientific), 50 U/mL penicillin/streptomycin (Gibco), 2 mM glutaMax (Gibco), 5 lg/mL human insulin (Sigma), and 5 3 10 25 M hydrocortisone hemisuccinate (UpJohn, SERB) at 378C in humidified CO 2 (5%) incubators and differentiated into hepatocyte-like cells by way of treatment with 1.8% dimethyl sulfoxide (DMSO; Hybrid-max, Sigma) for 2 weeks as described previously. (22) Engineered HepaRG cell lines were also used. The HepaRG-TR-PLK1
CA cell line enabling tetracycline-inducible expression of a constitutively active form of PLK1 (i.e., T210D mutant (23) ) was constructed as described for the HepaRG-TR-HBc cell line. (24) PHHs were obtained from surgical liver resections after informed consent of patients (kindly provided by Prof. Michel Rivoire [Centre L eon B erard, Lyon, France]; agreement numbers DC-2008-99 and DC-2008-101). PHHs were prepared as described previously (25) and were cultured in complete William's medium supplemented with 1.8% DMSO.
HBV INFECTION AND ANALYSIS OF VIRAL PARAMETERS DURING REPLICATION
dHepaRG cells and PHHs were infected as described previously, (26) with HBV inoculum prepared either from HepG2.2.15 or HepaAD38 cells. Intracellular accumulation of viral RNA and DNA, secretion of hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg) were monitored by quantitative polymerase chain reaction (qPCR), reverse transcription qPCR (RT-qPCR), southern blotting, and enzymelinked immunosorbent assay (ELISA), as described. (26) Briefly, HBeAg and HBsAg were quantified in culture medium by way of ELISA, using a chemiluminescence immunoassay kit (Autobio, China) according to the manufacturer's instructions. Total DNA was purified from infected cells using MasterPure Complete DNA Purification Kit (Epicentre). Southern blot analysis of HBV DNA was performed using equal amounts of total DNA, electrophoresed on 1.1% agarose gels, hybridized to HBV DNA radiolabeled with [a-32 P]CTP (22) and analyzed by autoradiography. Total RNA was extracted from infected cells using NucleoSpin RNA (MachereyNagel) and transcribed into complementary DNA using SuperScript III reverse transcriptase (Invitrogen, Carlsbad, CA). Real-time PCR for total HBV DNA and cccDNA was performed using LightCycler 96 (Roche) as described previously. (26, 27) 
TRANSFECTIONS, PLASMIDS, AND SMALL INTERFERING RNAs
Transient transfections in HEK293T cells were performed by employing Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. HBc-WT (EL43), HBc-3A (EL113), and HBc-3D (EL114) were kindly provided by Dr. Daniel Loeb, derived from EL43 plasmid. (28) The CTD-GST fusion protein plasmids GST-HCTD141 (CTD WT) and GST-HCTD141-AAAAAAA (CTD 7A) (7) were a kind gift from Dr. Jianming Hu. siRNAs (Smart pool grade; Dharmacon) for PLK1, HBV, and hepatitis C virus (HCV) (5-25 nM) were transfected in HBV-infected HepaRG or PHHs using Dharmafect I (Dharmacon) following the manufacturer's protocol.
HUMANIZED FRG MOUSE MODEL AND HBV INFECTION
All animal studies were reviewed and approved by our local ethics committee. Highly immunosuppressed FRG mice deficient in T cells, B cells, and natural killer cells were used (29) and maintained in a pathogenfree facility. High-quality cryopreserved human hepatocytes were purchased (BD, Biosciences) and injected through an intrasplenic route into 2-to 3-month old mice as described previously. (30) Liver humanized FRG mice featuring serum production of human albumin, at least 5 mg/mL, were infected with 200 lL of HBV inoculums (1.10 8 virus genome equivalents [veg] to 1.10 9 veg in phosphate-buffered saline) through an intraperitoneal route. (30) Mice were treated with intraperitoneal injection of BI-2536 (10 mg/kg twice a week) for 1 month. Serum was harvested every week by retro-orbital bleeding and stored at 2808C in aliquots for further antigenemia and viremia analysis. Mice were sacrificed at week 8 postinfection and hepatic tissues were frozen and processed for virologic parameter analyses or fixed in formalin and embedded in paraffin for immune-staining.
CAPSID MIGRATION ASSAY
The intracellular formation/accumulation of HBV nucleocapsids in in vitro2infected hepatocytes or in mousederived liver resection was accessed from cell or liver lysate by way of native agarose gel electrophoresis followed by transfer onto the enhanced chemiluminescence membrane and western blot analysis, as described previously. (6, 31) IN VITRO PLK1 KINASE ASSAYS Assays were performed as described previously (10) using recombinant PLK1 (BPS Bioscience, Protein One). Core protein was immunopurified from the HepaRG-TR-HBc cell line or purchased from Meridian Life Science, Inc. Site-directed mutagenesis of putative PLK1 phosphorylation sites in HBc-WT and HBc-3D was performed employing the Quick-Change Lightning site-directed mutagenesis Kit (Agilent). Point mutations in the GST-CTD-WT and GST-CTD-7A plasmids were introduced following the same procedure. Mutations were confirmed by DNA sequencing. For protein staining, PageBlue Protein Staining Solution (ThermoFisher) was used according to the manufacturer's protocol.
STATISTICAL ANALYSIS
Statistical analysis was performed using two-way analysis of variance, t tests, or nonparametric MannWhitney tests using GraphPad Prism software. For all tests, P 0.05, P 0.01, and P 0.001 were considered statistically significant.
Results
PLK1 IS ACTIVATED BY HBV INFECTION IN NON-DIVIDING/ DIFFERENTIATED HEPATOCYTES
Our earlier studies demonstrated that (1) HBx activates the mitotic S/T kinase PLK1, in a conditional HBx-expressing cell line, (11) (2) PLK1 activation initiates proteasomal degradation of chromatin modifying nuclear proteins SUZ12 and ZNF198, (10) and (3) SUZ12 down-regulation in HBV replicating hepatocytes results in expression of hepatic cancer stem cell markers and pluripotency genes. (32) We have also shown activation of PLK1 in HBV-replicating HepAD38 cells, (10) further suggesting a link between HBV infection and PLK1 activation. However, it has yet to be determined whether PLK1 activation occurs in the context of physiologic infection of nondividing, differentiated, and nontransformed hepatocytes. To this end, PHHs and dHepaRG cells were infected with HBV and expression and activation of PLK1 was quantified. Upon infection of dHepaRG cells, PLK1 messenger RNA (mRNA) increased by 15-fold 24 hours postinfection, followed by a constant level of expression of 3-to 5-fold from 48 to 168 hours postinfection (Fig. 1A) . This resulted in a transient increase in PLK1 protein levels (Fig. 1B) . More interestingly, an increase in PLK1 phosphorylation on S137 and/or T210, indicative of PLK1 activation, was detected as a function of HBV infection by immunoblotting (Fig. 1B) and immunofluorescence microscopy ( Fig. 1C) employing phospho-specific PLK1 antibodies. Remarkably, this activation of PLK1 by HBV infection was also detected by immunoblots of lysates from various preparations of PHHs (representative blots are shown in Fig. 1D ).
PLK1 INHIBITORS, INCLUDING BI-2536, SUPPRESS HBV DNA ACCUMULATION IN PERSISTENTLY HBV-INFECTED HEPATOCYTES
To test whether PLK1 activation has a proviral effect, dHepaRG cells were infected with HBV virions and on day 7 postinfection, when infection had reached a plateau in terms of viral replication, cells were treated with various PLK1 inhibitors. Specifically, increasing concentration of adenosine triphosphate (ATP)-competitive (i.e., BI-2536 and BI 6727) or non-ATP-competitive (i.e., MLN 0905 and ON 01910) PLK1 inhibitors were added for 3 days; accumulation of intracellular HBV DNA was measured by way of Southern blotting and qPCR (Supporting Fig.  S1A,B ). Among all drugs tested, BI-2536 was the most active and selected for further studies, after monitoring batch-to-batch stability (Supporting Fig. S2 ). HBV-infected dHepaRG treated with BI-2536 on day 7 postinfection exhibited no effect on levels of secreted HBeAg and HBsAg, or intracellular viral RNA (Fig.  2A) . Interestingly, BI-2536 significantly inhibited synthesis of total HBV DNA, with an effective concentration at 50% (EC 50 ) of approximately 4 nM ( Fig. 2A) , in the absence of any toxicity (cytotoxic concentration at 50%) of approximately 10 lM Fig. 2B ). Interestingly, BI-2536 reduced the level of capsid (i.e., assembled HBc/core protein) detected by immunofluorescence microscopy ( Fig. 2C ) with an antibody recognizing HBc assembled into capsid, and not monomeric forms of HBc (Supporting Fig. S3 ). Finally, BI-2536 was shown to strongly (up to 95%) and dose-dependently reduce the formation/accumulation of HBV nucleocapsids in infected cells (Fig. 2D) . Taken together, these results demonstrate that PLK1 inhibition by BI-2536 affects the assembly of HBV capsids, as specific HBc assembly inhibitors (such as BAY41-4109 or AT130) do, thereby inhibiting subsequent rcDNA synthesis. Similar results were also obtained in HBV-infected PHHs (Fig. 3) , with an EC 50 at approximately 50 nM. Interestingly, in this model, a trend toward an increase in intracellular viral RNA was observed (Fig. 3A) , thus inversely correlating with total DNA decrease. This corroborates the hypothesis that rcDNA synthesis is likely inhibited by an impaired assembly of capsids around pgRNA.
We also analyzed the effect of BI-2536 on the establishment of HBV infection and found that the antiviral effect was even greater with not only an effect on neosynthesis of HBV DNA but also effect on other measured viral parameters (Supporting Fig. S4 ).
LOSS-OF-FUNCTION OF PLK1 SUPPRESSES HBV DNA ACCUMULATION IN INFECTED HEPATOCYTES
To conclusively establish that PLK1 is a proviral factor, we investigated effect of loss of function of PLK1 on HBV replication by siRNA-mediated knockdown of PLK1 (siPLK1). As controls, we employed siRNAtargeting HBV transcripts (siHBV; positive control), and siRNA against HCV (siHCV) serving as negative control. The effectiveness of PLK1 knockdown by siRNA transfection was determined by quantification of PLK1 mRNA levels as a function of time after transfection (data not shown). Transfection of siPLK1 reduced by nearly 90% endogenous level of PLK1 mRNA at 72 hours after transfection, whereas all nontargeting siRNAs had no effect on PLK1 mRNA levels (Fig. 4A) . Transfection of increasing amounts of siPLK1, ranging from 5 to 25 nM in HBV-infected dHepaRG cells, resulted in a progressive reduction of 50% to nearly 70% in the accumulation of intracellular HBV DNA (Fig. 4A ). By contrast, transfection of 25 nM siHCV had a minimal effect,
FIG. 3. Effect of BI-2536 on HBV replication in nondividing
and nontransformed PHHs. PHHs were infected with 100 vge/cell of HBV for 4 days followed by treatment with increasing concentration of PLK1 inhibitor BI-2536, as indicated, for 3 days. (A) Quantification of secreted HBsAg and HBeAg by ELISA using supernatants of HBV-infected PHHs on day 7 postinfection. Total RNA and DNA extracted from HBV infected cells, day 7 postinfection, were analyzed by HBV-specific RT-qPCR or qPCR, normalized to housekeeping genes, and compared with mock-treated cells. Fold change in expression or secretion quantified relative to untreated controls are expressed as the mean 6 standard error of the mean of at least three independent experiments. (B) Representative Southern blotting (n 5 3). Total DNA extracted from cells on day 7 postinfection was analyzed by way of agarose gel electrophoresis, transferred onto a nylon membrane, and hybridized to a radioactive HBV probe as described previously. (22) whereas transfection of 25 nM siHBV reduced HBV DNA by nearly 80% (Fig. 4A) . With siPLK1, we again observed a decreased accumulation of assembled HBc within infected cells by way of immunofluorescence using an antibody recognizing assembled capsids (Fig. 4B) and by way of native capsid migration assay (Fig. 2D) , thus confirming the potential relationship between proviral action of PLK1, formation of HBV capsids, and decrease in newly synthetized rcDNA. Similar results were obtained in HBVinfected PHH cultures transfected for 72 hours with siRNAs targeting PLK1, HBV, or an irrelevant target (Fig. 4C) . Specifically, Southern blot analyses demonstrated a 50% reduction in HBV DNA by transfection of siPLK1, a 10% reduction with siHCV, and a 65% reduction with siHBV (Fig. 4D) .
A MODEST GAIN-OF-FUNCTION OF PLK1 IS ASSOCIATED WITH INCREASED HBV REPLICATION
To investigate the effect of gain-of-function of activated PLK1 on HBV replication, we generated an HepaRG cell line expressing a constitutively active form of PLK1 (PLK1 iii) were quantified respectively by qPCR, RT-qPCR, and cccDNA-specific qPCR. (27) whereas no effect on HBeAg secretion was observed (Supporting Fig. S5B ). This result suggests that active PLK1 enhances the formation of new viral genomes through reverse transcription of pgRNA; that is, it exerts a positive effect on capsid-assisted reverse transcription of pgRNA.
REDUCTION OF HBV VIREMIA IN LIVER-HUMANIZED INFECTED FRG MICE TREATED WITH BI-2536
To demonstrate the effect of BI-2536 on inhibition of HBV replication in vivo, we employed liverhumanized FRG mice (30) infected with HBV (5 3 10 8 vge/mouse). Once serum viremia reached 7 log 10 vge/ mL, antigenemia 5 log 10 IU/mL for HBsAg, and 2500 net control unit (NCU)/mL for HBeAg at week 4 postinfection, treatment was administered by way of intraperitoneal injection of 10 mg/kg of BI-2536 (or same concentration of DMSO diluted in saline) biweekly for 4 weeks. Serum viremia and antigenemia were monitored at the end of weeks 1, 2, 4, 6, 7, and 8, whereas weeks 6, 7, and 8 were those under treatment. Treated mice exhibited at week 8 a mean reduction of 1.406 log 10 6 0.26 in viremia (Fig. 5A) , whereas a minimal effect was observed on antigenemia (Fig. 5B,C) . Intraliver analyses using samples collected at euthanasia confirmed the reduction of total HBV DNA while showing no change in HBV RNA and cccDNA, further confirming the antiviral phenotype of BI-2536 (Fig. 5D) . If immunohistochemistry staining with a polyclonal anti-HBc antibody, which recognize all forms of HBc (Supporting Fig. S3 ), revealed a slight decrease in accumulation of this protein at the end of the treatment period (representative immunohistochemistry [IHC] shown in Fig. 6A ), an analysis of the accumulation of assembled capsid by native capsid migration assay confirmed the inhibitory effect of BI-2536 (representative IHC is shown in Fig. 6B,C) . This antiviral effect was obtained in the absence of toxicity as measured by monitoring mouse weight, secretion of human albumin in serum, and level of alanine aminotransferase (Supporting Fig. S6 ). It is worth noting that similar duration of treatment with IFN-a (25 lg/kg twice a week; n 5 5 mice treated) or entecavir (2.5 lg/mouse per day in drinking water; n 5 3 mice treated) in liver-humanized FRG mice led to a viremia reduction of 0.668 log 10 6 0.18 or 1.919 log 10 6 0.23, respectively (Supporting Fig. S7 ). These results indicate that a mean reduction of 1.406 log 10 6 0.26 in monotherapy obtained with BI-2536 was relevant and in between performance of IFN-a and entecavir in this model.
EFFECT OF THE COMBINATION OF BI-2536 WITH APPROVED OR INVESTIGATIONAL ANTI-HBV DRUGS
Our in vitro and in vivo data demonstrated that PLK1 inhibitors could be used as efficient and safe anti-HBV drugs. PLK1 inhibitor, including BI-2536, seems to target the capsid-associated reverse transcription of pgRNA into rcDNA. Other drugs also target this step of the viral life cycle, including nucleoside/ nucleotide analogs and core inhibitors (also called core protein allosteric modulators). However, all of these drugs have different molecular targets and therefore could be used in combination to enhance the inhibitory phenotype. To establish whether BI-2536 could be used in combination with nucleoside/nucleotide analogs or core protein allosteric modulators without leading to antagonistic effect, we combined these molecules to treat infected dHepaRG cells. A combination of BI-2536 and IFN-a was also included. As expected, only BI-2536 1 IFN-a treatment led to a reduction in HBeAg secretion (Fig. 7A) , whereas all other combinations led to a sharp reduction of intracellular HBV DNA (Fig. 7B) . No obvious antagonism was evidenced for all combinations tested, thus suggesting that these drugs could be further considered for combination studies.
HBc IS A SUBSTRATE FOR PLK1 IN VITRO
During established infection, inhibition of PLK1 by treatment with BI-2536 suppressed only viral DNA synthesis (Figs. 2A, and 3A,B) , suggesting that PLK1 may have a role in capsid-associated reverse transcription of pgRNA into rcDNA. Conversely, inhibition of PLK1 could prevent these processes, based on capsid assembly. Because HBc has an essential and dynamic role in this process of capsid assembly, pgRNA encapsidation, and rcDNA biosynthesis, we investigated whether HBc is a PLK1 phosphorylation substrate.
To determine whether HBc is a direct target of PLK1, we performed in vitro kinase assays with purified recombinant HBc and PLK1 (Fig. 8) . We observed in vitro PLK1 phosphorylation of HBc using either recombinant HBc or HBc isolated from HepaRG-TR-HBc cells (Fig. 8A) ; furthermore, addition of 500nM BI-2536 inhibited this phosphorylation (Fig. 8A, left panel) . The C-terminal domain of HBc (CTD), spanning amino acids 143 to 183 (Fig. 8B) , contains 8 S/T residues. We performed in vitro PLK1 kinase assays with GST-CTD fusion peptide isolated from transfected cells and featuring either wild-type or mutated CTD sequences at all S/T sites. This approach was validated by showing that fusion protein with seven (not including T147) or all eight S/T positions mutated exhibited absence of PLK1 phosphorylation (Fig. 8B ). PLK1 requires a priming phosphorylation of its substrate, usually by CDK1 or CDK2 at SP sites. Interestingly, HBc is known to be phosphorylated by CDK2 at three SP phosphorylation sites (Fig. 8B ). Accordingly, we tested whether HBc proteins containing S to A or S to D substitutions at all three SP positions (labeled as 3A or 3D) could serve as PLK1 substrates. Interestingly, only the phosphomimetic substitutions-S155D, S162D, and S170D (referred to as 3D)-exhibited phosphorylation by PLK1 (Fig. 8C) . Next, we observed that S168A exhibited significantly reduced phosphorylation in the context of the phospho-mimetic substitutions at SP sites, whereas no difference in the phosphorylation by PLK1 was detected by T146A and T147A substitutions (Fig.  8D) . Single point mutations at residues 168, 176, and 178, again in the context of the phospho-mimetic substitutions at SP sites, resulted in significant reduction of HBc phosphorylation by PLK1 (Fig. 8E) . Therefore, we conclude that S168, S176, and S178 are PLK1 phosphorylation sites in vitro.
Discussion
The hepatitis B virus (HBV) is one of the most important human oncogenic viruses.
(1,2) Approximately 250 million individuals worldwide are chronically infected with HBV, having increased risk for developing HCC. (1, 2) If clinicians dispose of several anti-HBV drugs, they have limited chemotherapeutic options for HCC. It is thus crucial to identify novel molecules that target both virus biosynthesis and neoplastic transformation. In this study, we provide evidence that PLK1, a kinase already demonstrated to be involved in HCC, could represent a potential target to tackle both HBV replication and liver oncogenesis.
Earlier studies demonstrated that HBx activates PLK1 in a hepatocyte model cell line (11) and that PLK1 was activated in the HepAD38 cellular model of HBV replication. (10) However, this cellular model of viral replication does not model physiologic infection. In this study, using physiologically relevant HBV infection models comprising PHHs and HepaRG cells, we show that HBV infection leads to early activation of PLK1. Here, we show that PLK1 phosphorylation occurs upon HBV infection in nondividing and differentiated cells; the mechanism of PLK1 activation during HBV infection is yet to be determined. HBx protein, which is expressed very early after HBV infection, remains the main candidate for this activation, likely mediating PLK1 activation via the p38MAPK. (11, 33) Here, we provide evidence for the functional advantage to the viral life cycle of this early activation of PLK1 by HBV infection. Employing PLK1 pharmacological inhibitors and an RNA interference approach, we have shown that PLK1 enzymatic activity is crucial for maintenance of HBV replication in nondividing hepatocytes. Indeed, BI-2536, an ATP-dependent PLK1 inhibitor, drastically inhibited HBV replication in vitro in both HepaRG cells and PHHs, as well as in vivo in liver humanized FRG mice, without toxicity. Interestingly, the antiviral activity of BI-2536 was potent, with an EC 50 ranging from 5 to 50 nM, depending on the cell type used; such an antiviral efficacy is rarely obtained with host targeting agents and corresponds to the efficacy of direct acting agents including nucleoside analogs or assembly inhibitors. Accordingly, an in vivo antiviral activity was also obtained with BI-2536 in HBV-infected liver humanized FRG mice, and this antiviral activity was comparable to that obtained with entecavir or IFN-a in the same model. The RNA interference (RNAi) approach confirmed the PLK1 specificity, as kinase inhibitors are often nonspecific. The antiviral phenotype obtained by RNAi targeting PLK1 was also very strong in vitro. The use of such an approach in vivo using siRNA that could be specifically targeted to infected hepatocytes could represent an interesting alternative to pharmacological inhibitors, which may be quite toxic when administrated systemically. Recently, it has been shown that RNAi nanoparticles in complex with PLK1 siRNA, administered systemically, efficiently delivers PLK1 siRNA to the liver with no observable toxicity.
(34) Finally, we have also shown that BI-2536 could be combined in vitro and presented no antagonism to currently approved (i.e., IFN-a and tenofovir) anti-HBV drugs and Bay41-4109, (20) a representative core inhibitor, the latter being a novel class of inhibitors in current clinical development. (5) The molecular mechanism underlying the proviral role of PLK1 has not been completely determined in this study. Nevertheless, we have shown that a target of PLK1 is the capsid/core protein (HBc), which is responsible for capsid assembly around the pgRNA, and indirectly reverse-transcribed pgRNA, as the latter occurs only within capsids. PLK1-mediated phosphorylation requires prior phosphorylated primed substrates. Here, we present evidence that HBc is a direct target of PLK1 in vitro, and importantly, efficient phosphorylation of HBc required prior phosphorylation at positions S155/S162/S170, sites shown to be phosphorylated by CDK2. (7, 8) Our studies identified S168, S176, and S178 as PLK1 phosphorylation sites in vitro, dependent on prior phosphorylation of S155, S162, and S170. Thus, PLK1-mediated phosphorylation of HBc in a sequential phosphorylation process could directly mediate the dynamic events associated with capsid formation, pgRNA encapsidation, and reverse transcription. Further mechanistic studies and molecular tools (phospho-specific antibodies) are required to fully delineate this mechanism of PLK1 involvement.
Many other viral proteins are directly phosphorylated by PLK1, including the nonstructural 5A protein from HCV, (35) the mumps virus nucleoprotein, (36) and the parainfluenza virus 5 protein. (37) PLK1-mediated phosphorylation of the target can either lead to its degradation or change in function; therefore, PLK1 can either act as a proviral or antiviral factor. For HCV, PLK1 seems to be a proviral factor, as it contributes to the hyperphosphoryaltion of nonstructural 5A, (35) which is a crucial event to switch from a replicative cycle (i.e., amplification of viral RNA) to a productive one (i.e., generation and secretion of novel virions). Nevertheless, the use of anti-PLK1 drugs has only limited value to inhibit HCV replication, because the virus replicates better in vitro in dividing cells, thus precluding nontoxic PLK1 inhibition. However, in the case of HBV, this framework for a potential use of PLK1 targeting drugs does exist. Indeed, HBV only replicates in nondividing and highly differentiated cells. Although we have shown here that an anti-HBV phenotype could be obtained in vivo, more experiments are warranted to further demonstrate the safety of such a host targeting agent-based approach. Many PLK1 pharmacological inhibitors as well as strategies based on PLK1 silencing are in current development for treating several cancers (38) ; a repositioning of such drugs for the treatment of chronic hepatitis B patients could be foreseen. The fact that PLK1 inhibitors could reinforce the inhibition of the neosynthesis of encapsidated rcDNA, as nucleoside analogs already do represent an excellent framework for the potential development of combination therapies.
